234 related articles for article (PubMed ID: 22591130)
1. Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.
Ekman M; Lindgren P; Miltenburger C; Meier G; Locklear JC; Chatterton ML
Pharmacoeconomics; 2012 Jun; 30(6):513-30. PubMed ID: 22591130
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.
Woodward TC; Tafesse E; Quon P; Lazarus A
Pharmacoeconomics; 2010; 28(9):751-64. PubMed ID: 20623994
[TBL] [Abstract][Full Text] [Related]
3. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.
Bridle C; Palmer S; Bagnall AM; Darba J; Duffy S; Sculpher M; Riemsma R
Health Technol Assess; 2004 May; 8(19):iii-iv, 1-187. PubMed ID: 15147609
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis.
Fajutrao L; Paulsson B; Liu S; Locklear J
Clin Ther; 2009 Jun; 31 Pt 1():1456-68. PubMed ID: 19698903
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder.
Calvert NW; Burch SP; Fu AZ; Reeves P; Thompson TR
J Manag Care Pharm; 2006 May; 12(4):322-30. PubMed ID: 16792438
[TBL] [Abstract][Full Text] [Related]
6. Quetiapine: a pharmacoeconomic review of its use in bipolar disorder.
Plosker GL
Pharmacoeconomics; 2012 Jul; 30(7):611-31. PubMed ID: 22559293
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes.
Sawyer L; Azorin JM; Chang S; Rinciog C; Guiraud-Diawara A; Marre C; Hansen K
J Med Econ; 2014 Jul; 17(7):508-19. PubMed ID: 24720805
[TBL] [Abstract][Full Text] [Related]
8. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine.
Gianfrancesco F; Pesa J; Wang RH
J Manag Care Pharm; 2005 Apr; 11(3):220-30. PubMed ID: 15804206
[TBL] [Abstract][Full Text] [Related]
9. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.
Soares-Weiser K; Bravo Vergel Y; Beynon S; Dunn G; Barbieri M; Duffy S; Geddes J; Gilbody S; Palmer S; Woolacott N
Health Technol Assess; 2007 Oct; 11(39):iii-iv, ix-206. PubMed ID: 17903393
[TBL] [Abstract][Full Text] [Related]
10. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression.
Rajagopalan K; Meyer K; O'Day K; Denno M; Loebel A
J Med Econ; 2015; 18(10):821-7. PubMed ID: 25985265
[TBL] [Abstract][Full Text] [Related]
12. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Jing Y; Kim E; You M; Pikalov A; Tran QV
J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
[TBL] [Abstract][Full Text] [Related]
13. Quetiapine: a review of its use in the management of bipolar depression.
Sanford M; Keating GM
CNS Drugs; 2012 May; 26(5):435-60. PubMed ID: 22519923
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom.
McKendrick J; Cerri KH; Lloyd A; D'Ausilio A; Dando S; Chinn C
J Psychopharmacol; 2007 Aug; 21(6):588-96. PubMed ID: 17050661
[TBL] [Abstract][Full Text] [Related]
15. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
[TBL] [Abstract][Full Text] [Related]
16. Typical and atypical antipsychotics in bipolar depression.
Gao K; Gajwani P; Elhaj O; Calabrese JR
J Clin Psychiatry; 2005 Nov; 66(11):1376-85. PubMed ID: 16420074
[TBL] [Abstract][Full Text] [Related]
17. Newer treatment studies for bipolar depression.
Gao K; Calabrese JR
Bipolar Disord; 2005; 7 Suppl 5():13-23. PubMed ID: 16225556
[TBL] [Abstract][Full Text] [Related]
18. Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.
Yu AP; Atanasov P; Ben-Hamadi R; Birnbaum H; Stensland MD; Philips G
Value Health; 2009; 12(5):708-15. PubMed ID: 19508658
[TBL] [Abstract][Full Text] [Related]
19. Acute and maintenance treatments for bipolar depression.
Ketter TA
J Clin Psychiatry; 2014 Apr; 75(4):e10. PubMed ID: 24813411
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
Taneja C; Papakostas GI; Jing Y; Baker RA; Forbes RA; Oster G
Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
